Drug Res (Stuttg) 2020; 70(04): 151-157
DOI: 10.1055/a-1112-7032
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Toxicity of Atenolol and Propranolol on Rat Heart Mitochondria

Enayatollah Seydi
1   Department of Occupational Health and Safety Engineering, School of Health, Alborz University of Medical Sciences, Karaj, Iran
2   Research Center for Health, Safety and Environment, Alborz University of Medical Sciences, Karaj, Iran
,
Yasaman Tabbati
3   Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
,
Jalal Pourahmad
3   Department of Pharmacology and Toxicology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
› Author Affiliations
Further Information

Publication History

received 20 December 2019

accepted 27 January 2020

Publication Date:
02 March 2020 (online)

Abstract

Propranolol and atenolol are known as β receptor blocker drugs. These drugs are used to treat some heart diseases. There are controversies in the relationship between the use of beta-blocker drugs and the level of reactive oxygen species (ROS). Mitochondria as one of the most important sources of ROS are considered as one of the targets of drug-induced cardiotoxicity. The aim of this study was to evaluate the effects of propranolol and atenolol on mitochondria isolated from the heart. To achieve this aim, several markers of mitochondrial and cellular toxicity were evaluated. The key results of this study are the increased ROS level, collapse in mitochondrial membrane potential (MMP), mitochondrial swelling and cytochrome c release as well as disruption of respiratory chain complex II in mitochondria in isolated heart mitochondria after exposure to propranolol and atenolol. The results indicate an increase in caspase-3 activity and a decrease in the ATP level in cardiomyocytes after exposure to propranolol and atenolol. The underlying mechanisms of propranolol and atenolol induced cardiotoxicity may be associated with alterations in mitochondrial function, oxidative stress, and changes in the mitochondrial membrane.

 
  • References

  • 1 Goldberger JJ, Bonow RO, Cuffe M. et al. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. J Am Coll Cardiol 2015; 66: 1431-1441
  • 2 Prins KW, Neill JM, Tyler JO. et al. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail 2015; 3: 647-653
  • 3 Silverman DN, Plante TB, Infeld M. et al. Association of beta-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Netw Open 2019; 2: e1916598
  • 4 Dezsi CA, Szentes V. The Real Role of beta-Blockers in Daily Cardiovascular Therapy. Am J Cardiovasc Drugs 2017; 17: 361-373
  • 5 DiNicolantonio JJ, Fares H, Niazi AK. et al. beta-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart 2015; 2: e000230
  • 6 Imamura Y, Wu X, Noda A. et al. Side-chain metabolism of propranolol: involvement of monoamine oxidase and mitochondrial aldehyde dehydrogenase in the metabolism of N-desisopropylpropranolol to naphthoxylactic acid in rat liver. Life Sci 2002; 70: 2687-2697
  • 7 Finsterer J, Zarrouk-Mahjoub S. Mitochondrial toxicity of cardiac drugs and its relevance to mitochondrial disorders. Expert Opin Drug Metab Toxicol 2015; 11: 15-24
  • 8 Debbasch C, Pisella P-J, De Saint Jean M. et al. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved β-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001; 42: 2525-2533
  • 9 Brohee L, Peulen O, Nusgens B. et al. Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. Sci Rep 2018; 8: 7050
  • 10 Iwai T, Tanonaka K, Kasahara S. et al. Protective effect of propranolol on mitochondrial function in the ischaemic heart. Br J Pharmacol 2002; 136: 472-480
  • 11 Kaasik A, Kuum M, Joubert F. et al. Mitochondria as a source of mechanical signals in cardiomyocytes. Cardiovasc Res 2010; 87: 83-91
  • 12 Montoya A, Varela-Ramirez A, Dickerson E. et al. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. Biomed J 2019; 42: 155-165
  • 13 Wang F, Liu H, Wang F. et al. Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. Mol Med Rep 2018; 17: 5213-5221
  • 14 Pourahmad J, Hosseini MJ. Application of isolated mitochondria in toxicological and clinical studies. Iran J Pharm Res 2012; 11: 703
  • 15 Siasos G, Tsigkou V, Kosmopoulos M. et al. Mitochondria and cardiovascular diseases-from pathophysiology to treatment. Ann Transl Med 2018; 6: 256
  • 16 Zhao Q, Sun Q, Zhou L. et al. Complex Regulation of Mitochondrial Function During Cardiac Development. J Am Heart Assoc 2019; 8: e012731
  • 17 Hu D, Wu CQ, Li ZJ. et al. Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. Toxicol Appl Pharmacol 2015; 284: 134-141
  • 18 Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006; 222: 233-239
  • 19 Munro D, Treberg JR. A radical shift in perspective: mitochondria as regulators of reactive oxygen species. J Exp Biol 2017; 220: 1170-1180
  • 20 Zhao RZ, Jiang S, Zhang L. et al. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med 2019; 44: 3-15
  • 21 Rezaiean Mehrabadi A, Jamshidzadeh A, Rashedinia M. et al. Study of the Effects of ATP Suppliers and Thiol Reductants on Toxicity of Pioglitazone in Isolated Rat Liver Mitochondria. Iran J Pharm Res 2015; 14: 825-832
  • 22 Kornfeld OS, Hwang S, Disatnik MH. et al. Mitochondrial reactive oxygen species at the heart of the matter: new therapeutic approaches for cardiovascular diseases. Circ Res 2015; 116: 1783-1799
  • 23 Moris D, Spartalis M, Spartalis E. et al. The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox. Ann Transl Med 2017; 5: 326
  • 24 Panth N, Paudel KR, Parajuli K. Reactive oxygen species: A key hallmark of cardiovascular disease. Adv Med 2016; 2016: 9152732
  • 25 Taverne YJ, Bogers AJ, Duncker DJ. et al. Reactive oxygen species and the cardiovascular system. Oxidative med cell longev. 2013 2013. DOI: 10.1155/2013/862423. Epub 2013 Apr 22.
  • 26 Miura T, Wang R, Kametani R. et al. Differential Effect of Beta-blockers on Mitochondrial Function and Cell Death in Heart Failure. J Card Fail 2005; 11: S244
  • 27 Eskandari MR, Moghaddam F, Shahraki J. et al. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica 2015; 45: 79-87
  • 28 Zhao Y, Ye L, Liu H. et al. Vanadium compounds induced mitochondria permeability transition pore (PTP) opening related to oxidative stress. J Inorg Biochem 2010; 104: 371-378
  • 29 Salimi A, Eybagi S, Seydi E. et al. Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. Xenobiotica 2016; 46: 82-93
  • 30 Baracca A, Sgarbi G, Solaini G. et al. Rhodamine 123 as a probe of mitochondrial membrane potential: Evaluation of proton flux through F(0) during ATP synthesis. Biochim Biophys Acta 2003; 1606: 137-146
  • 31 Tafreshi N, Hosseinkhani S, Sadeghizadeh M. et al. The influence of insertion of a critical residue (Arg356) in structure and bioluminescence spectra of firefly luciferase. J Biol Chem 2007; 282: 8641-8647
  • 32 Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail 2002; 8: 173-177 90
  • 33 Budni P, Pedrosa RC, Dalmarco EM. et al. Carvedilol enhances the antioxidant effect of vitamins E and C in chronic Chagas heart disease. Arq Bras Cardiol 2013; 101: 304-310
  • 34 Gomes A, Costa D, Lima JL. et al. Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species?. Bioorg Med Chem 2006; 14: 4568-4577
  • 35 Nakamura K, Murakami M, Miura D. et al. Beta-Blockers and Oxidative Stress in Patients with Heart Failure. Pharmaceuticals (Basel) 2011; 4: 1088-1100
  • 36 Kadenbach B, Ramzan R, Moosdorf R. et al. The role of mitochondrial membrane potential in ischemic heart failure. Mitochondrion 2011; 11: 700-706
  • 37 Xu M, Wang Y, Ayub A. et al. Role of Mitochondrial Membrane Potential in Cardiac Protection against Ischemia. Myocardial Ischemia and Preconditioning. Springer; 2003. p 205-218
  • 38 Amacher DE. Drug-associated mitochondrial toxicity and its detection. Curr Med Chem 2005; 12: 1829-1839
  • 39 Sanz MN, Sanchez-Martin C, Detaille D. et al. Acute mitochondrial actions of glitazones on the liver: a crucial parameter for their antidiabetic properties. Cell Physiol Biochem 2011; 28: 899-910
  • 40 Chapa-Dubocq X, Makarov V, Javadov S. Simple kinetic model of mitochondrial swelling in cardiac cells. J Cell Physiol 2018; 233: 5310-5321
  • 41 Shaki F, Hosseini MJ, Ghazi-Khansari M. et al. Toxicity of depleted uranium on isolated rat kidney mitochondria. Biochim Biophys Acta 2012; 1820: 1940-1950